Kimberly-Clark Q3 2026 earnings call covers the Kenvue integration, $1.9 billion cost synergies, 2027 EPS dilution and North ...

Operator: Good afternoon, everyone. Thank you for standing by. Welcome to the CytomX Therapeutics third quarter 26 financial ...

Executive Vice President and Chief Financial Officer - Tim O'Brien ...

MAG Aerospace reports on the significance of a common operating picture (COP) in consolidating vast data for improved ...

Market rumors have recently emerged claiming that Kunlunxin is targeting an IPO valuation of 50 billion U.S. dollars, a ...

BancAnalysts Association of Boston Conference 2026 November 5, 2026 2:10 PM ESTCompany ParticipantsKevin Blair ...

<?xml encoding="utf-8" ?> Quantinuum QNT reported third-quarter financial results on Thursday. The transcript from the ...

India, Nov. 5 -- A student in Lyon opens a chatbot to polish an essay before the bell rings. A teacher in a Delhi classroom ...

The FDA accepted Palvella Therapeutics’ NDA for QTORIN rapamycin in microcystic lymphatic malformations and granted priority ...